| Fiscal period | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Period End Date | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 |
|---|
| Revenues: Net product sales | 7,629.20 | 7,078.00 | 6,893.70 | 12,117.20 | 5,567.60 | 4,834.40 | 4,106.20 | 3,718.46 | 3,338.39 | 2,689.48 |
| Revenues: Collaboration revenue: Bayer HealthCare | -- | -- | 2,058.40 | 1,409.30 | 1,186.10 | 1,188.80 | 1,076.70 | 938.05 | 744.27 | 580.49 |
| Revenues: Collaboration revenue: Sanofi-aventis | -- | -- | 2,855.70 | 1,902.20 | 1,186.40 | 1,426.80 | 1,111.10 | 877.19 | 658.67 | 758.87 |
| Revenues: Contract manufacturing | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenues: Contract research and development | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenues: Research progress payments | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenues: Technology Licensing & Other Revenue | 515.00 | 536.10 | 365.10 | 281.20 | 557.00 | 413.40 | 416.80 | 338.52 | 119.10 | 74.89 |
| Revenues: Collaboration revenue: Roche | -- | -- | -- | 361.80 | -- | -- | -- | -- | -- | -- |
| Revenues: Collaboration revenue | 6,057.80 | 5,503.10 | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Revenues | 14,202.00 | 13,117.20 | 12,172.90 | 16,071.70 | 8,497.10 | 7,863.40 | 6,710.80 | 5,872.23 | 4,860.43 | 4,103.73 |
| Cost of goods sold | 1,087.30 | 932.10 | 800.00 | 1,773.10 | 491.90 | 362.30 | 180.00 | 202.51 | 194.62 | 241.70 |
| Cost of collaboration manufacturing | 883.20 | 883.70 | 760.40 | 664.40 | 628.00 | 419.90 | 254.10 | 194.55 | 105.07 | 151.01 |
| Gross Profit | -- | 11,301.40 | -- | 13,634.20 | 7,377.20 | 7,081.20 | -- | 5,475.17 | 4,560.73 | 3,711.02 |
| Research and development | 5,132.00 | 4,439.00 | 3,592.50 | 2,908.10 | 2,735.00 | 3,036.60 | 2,186.10 | 2,075.14 | 2,052.30 | 1,620.58 |
| Acquired in-process research and development | 101.00 | 186.10 | 255.10 | -- | -- | -- | -- | -- | -- | -- |
| General and Administrative | 2,954.40 | 2,631.30 | 2,115.90 | 1,824.90 | 1,346.00 | 1,834.80 | 1,556.20 | 1,320.43 | 1,177.70 | 838.53 |
| Other operating (income) expense, net | (53.40) | 2.10 | 89.90 | 45.60 | 280.40 | -- | -- | -- | -- | -- |
| Total Operating Expense | 10,211.30 | 9,070.10 | 7,434.00 | 7,124.90 | 4,920.50 | 5,653.60 | 4,176.40 | 3,792.64 | 3,529.69 | 2,851.81 |
| Income (loss) from operations | 3,990.70 | 4,047.10 | 4,738.90 | 8,946.80 | 3,576.60 | 2,209.80 | 2,534.40 | 2,079.59 | 1,330.74 | 1,251.92 |
| Interest expense | 55.20 | 73.00 | 59.40 | 57.30 | 56.90 | 30.20 | 28.20 | 25.12 | 7.20 | 14.24 |
| Earnings (Loss in) from Amgen-Regeneron Partners | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Investment income | -- | -- | -- | -- | -- | -- | -- | -- | -- | 6.28 |
| Other contract income | 844.40 | 225.20 | 179.30 | 436.30 | 290.70 | 249.50 | 47.30 | 24.04 | 6.27 | -- |
| Gain (Loss) on early extinguishment of debt | -- | -- | -- | -- | -- | -- | -- | -- | -- | (18.86) |
| Other income (expense) | 789.20 | 152.20 | 119.90 | 379.00 | 233.80 | 219.30 | 19.10 | (1.08) | (0.93) | (26.82) |
| Pre-Tax Income | 4,779.90 | 4,199.30 | 4,858.80 | 9,325.80 | 3,810.40 | 2,429.10 | 2,553.50 | 2,078.51 | 1,329.82 | 1,225.10 |
| Income tax expense (benefit) | 367.30 | 245.70 | 520.40 | 1,250.50 | 297.20 | 313.30 | 109.10 | 880.00 | 434.29 | 589.04 |
| Current - Federal | -- | 667.90 | 968.50 | 1,429.80 | 199.00 | 444.60 | 223.70 | -- | -- | -- |
| Deferred - Federal | -- | (834.50) | (797.70) | (423.20) | 109.00 | (132.00) | 687.60 | -- | -- | -- |
| Current - foreign | -- | 407.90 | 290.90 | (38.40) | 21.40 | (2.60) | 20.60 | -- | -- | -- |
| Current - State | -- | 7.70 | 7.40 | 6.20 | 1.20 | 1.90 | 4.80 | -- | -- | -- |
| Deferred - foreign | -- | 3.20 | 54.00 | 276.70 | (31.40) | 3.10 | (825.70) | -- | -- | -- |
| Deferred - state | -- | (6.50) | (2.70) | (0.60) | (2.00) | (1.70) | (1.90) | -- | -- | -- |
| Net income (loss) before cumulative effect of a change in accounting principle | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cumulative effect of adopting Statement of Financial Accounting Standards | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net income attributable to common shareholders | 4,412.60 | 3,953.60 | 4,338.40 | 8,075.30 | 3,513.20 | 2,115.80 | 2,444.40 | 1,198.51 | 895.52 | 636.06 |
| Continuing Operations- (Basic) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cumulative effect of adopting | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Earnings Per Share (Basic) | 40.90 | 37.05 | 40.51 | 76.40 | 32.65 | 19.38 | 22.65 | 11.27 | 8.55 | 6.17 |
| Continuing Operations- (Diluted) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Earnings Per Share (Diluted) | 38.34 | 34.77 | 38.22 | 71.97 | 30.52 | 18.46 | 21.29 | 10.34 | 7.70 | 5.52 |
| Weighted Average Shares Outstanding (Basic) | 107.90 | 106.70 | 107.10 | 105.70 | 107.60 | 109.20 | 107.90 | 106.34 | 104.72 | 103.06 |
| Weighted Average Shares Outstanding (Diluted) | 115.10 | 113.70 | 113.50 | 112.20 | 115.10 | 114.60 | 114.80 | 115.95 | 116.37 | 115.23 |